NCT05911230Recruiting
Advanced Diffusion MRI to Differentiate Tumor Recurrence From Pseudoprogression in Patients With Glioblastoma and Brain Metastases
Summary
This pilot study investigates whether advanced diffusion-weighted MRI (ADW-MRI) can differentiate between true tumor progression (TP) and a pseudoprogression (PsP) in patients with glioblastoma (GBM) or brain metastases.
Inclusion criteria
• Patients with histopathologically proven glioblastoma or brain metastasis and suspected tumor progress on standard MRI after first line therapy and who are candidates for elective surgical resection. • Able to give informed consent
Exclusion criteria
• Contraindications to MRI (e.g. claustrophobia, pacemaker or other implants without MRI-approval, pregnancy) • Patients in a life-threatening condition • Patients in need of emergent surgery • Histopathological analyses of insufficient quality • Unable to give informed consent • Age \<18 Years
Contacts
The trial team's contact details are shown on request.
See the official trial record- Status
- Recruiting
- Phase
- No phase (N/A)
- Study type
- Interventional
- Countries
- Switzerland
- Sponsor
- University Hospital, Basel, Switzerland(Other)
- Protocol no.
- 2022-00888; ko23Cordier
- Conditions
- Glioblastoma (GBM)
- Interventions
- Diagnostic test
Treatments studied
- Advanced diffusion-weighted MRI (ADW-MRI)
Locations · 1
- Basel, SwitzerlandUniversity Hospital BaselRecruiting at this site
In total, worldwide, the only site listed in the registry is recruiting.
Site status per the ClinicalTrials.gov registry (last update posted: January 29, 2025).
This status may have changed and says nothing about your eligibility: before taking any step, check with your oncologist or the site.
See also
Other versions
These results are indicative and do not replace medical advice — discuss them with your doctor.